CD69 and metabolic dysfunction-associated steatotic liver disease: There was also an increase in the percentage of CD69+iNKT cells in DILI patients (25.3 ± 9.4) with respect to NAFLD patients without significant liver fibrosis (F ≤ 1) (6.1 ± 2.5, p = 0.045) and healthy controls (10.1 ± 1.9, p = 0.042) (Figure 2).